Substance / Medication

Simoctocog alfa

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Estimation of Nuwiq(simoctocog alfa) activity using one-stage and chromogenic assays-Results from an international comparative field study.
Tiefenbacher Stefan, Albisetti Manuela, Baker Peter et al. · Haemophilia · 2019
PMID: 31106957ObservationalFull text (PMC)
Efficacy and safety of a recombinant factor VIII produced from a human cell line (simoctocog alfa).
Franchini Massimo, Mannucci Pier Mannuccio · Expert Opin Drug Saf · 2017
PMID: 28103444Observational
Simoctocog alfa (Nuwiq) in children: early steps in life's journey for people with severe hemophilia A.
Klukowska Anna, Sidonio Robert F, Young Guy et al. · Ther Adv Hematol · 2024
PMID: 38737006ReviewFull text (PMC)
Design of an international, phase IV, open-label study of simoctocog alfa in women/girls with hemophilia A undergoing surgery (NuDIMENSION).
Marquardt Natascha, Langer Florian, Holstein Katharina et al. · Ther Adv Hematol · 2024
PMID: 39624518OtherFull text (PMC)
Simoctocog alfa (Nuwiq®) in previously untreated patients with severe haemophilia A-Final efficacy and safety results from the NuProtect study.
Mathias Mary, Abraham Aby, Belletrutti Mark J et al. · Eur J Haematol · 2023
PMID: 37439123Other
Simoctocog Alfa (Nuwiq) in Previously Untreated Patients with Severe Haemophilia A: Final Results of the NuProtect Study.
Liesner Ri J, Abraham Aby, Altisent Carmen et al. · Thromb Haemost · 2021
PMID: 33581698TrialFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Simoctocog alfa (substance)
SNOMED CT
718853005
UMLS CUI
C4064080

Clinical Data

This intervention maps to 3 entities in the Healos knowledge graph.

3
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.